NFE2L2 and cancer: In preclinical studies, two common type 2 diabetes mellitus drugs (saxagliptin and sitagliptin), which prolong the NRF2 antioxidant response by inhibiting KEAP1C151 (a cysteine sensor causing constitutive NRF2 activation), increase the metastatic risk of several cancers.